SLS SELLAS Life Sciences Group Inc.

4
-0.3  -7%
Previous Close 4.3
Open 4.27
Price To Book 1.27
Market Cap 18,240,000
Shares 4,560,000
Volume 396,031
Short Ratio
Av. Daily Volume 310,544
Stock charts supplied by TradingView

NewsSee all news

  1. SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results

    - Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - - Clinically Significant Follow-up Data from Phase 1 Trial Continues to Support the Development

  2. SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer

  3. SELLAS Announces Reverse Stock Split

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Waiting on further guidance from FDA regarding future development - likely 1H 2019.
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 1/2 interim data due 1Q 2020.
Galinpepimut-S and Keytruda (pembrolizumab)
Solid tumors
Phase 3 trial planned for 4Q 2019 with interim data due 1Q 2020.
Galinpepimut-S
Acute Myeloid Leukemia (AML)
Phase 1/2 presentation due ASCO June 2018. 1-year PFS rate was 64% in the ITT group.
Galinpepimut-S and nivolumab
Ovarian cancer
Phase 2 initial data due by the end of 2019.
NeuVax
Ductal Carcinoma in Situ (DCIS)

Latest News

  1. SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results

    - Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - - Clinically Significant Follow-up Data from Phase 1 Trial Continues to Support the Development

  2. SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer

  3. SELLAS Announces Reverse Stock Split

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer